FEATURED CONTRIBUTED CONTENT
The Innovation Imperative: The Future of Drug Development
The impact of innovation is evident across a number of industries but has not been fully realized within the pharmaceutical industry. With rising R&D costs, a more crowded marketplace and increased focus on value demonstration, developers face mounting pressure in bringing drugs to market. Yet, opportunity exists to meet the growing health needs of the […]
The Evolution of Bioanalytical Outsourcing Partnerships
By Jim Datin, President and CEO, BioAgilytix Bioanalytical outsourcing has changed dramatically in the past 30 years, which isn’t surprising when you consider how our economy, the healthcare market, technology, and drugs themselves have changed in that same period. In order to keep up with external market pressures and the complexity of emerging large molecule […]
The Power of Insight
Good insight gives you the tools to create innovative products and services that meet customers’ needs at the point of need, transforming lives. However, many organisations find distilling large swathes of data into meaningful insights challenging. Download the white paper to learn: Tools for easily bringing your research to life How to turn data into […]
Building a Secure, Automated Quality System to Accelerate Time to Market
Today life science companies face a perfect storm of factors driving their costs up and sales down. With 40% of R&D costs linked to paper-based processes, legacy, manual processes pose a particular threat – costing life science companies billions of dollars a year and delaying product launch and commercialization*. Boston Scientific is tackling these challenges […]
Clinical Trials in Children with Impaired Mental Capacity
In the majority of clinical trials we undertake, the consent process is fairly straightforward; however, complex situations do arise. Pediatric clinical trials present unique challenges, as do those in patients who lack legal competence. In the instance of a mentally impaired child, it is important to determine the best approach for obtaining consent and assent as early as possible […]
Addressing Unmet Needs of Patients and Providers in Rare and Complex Disease
As the growth of rare and complex disease continues to skyrocket, more than ever, pharmaceutical manufacturers must address the unique challenges of providers and their patients to differentiate their brand. Providers and their staff have a lack of knowledge; they face continued time constraints, and with the growth of new products it’s difficult to keep […]
The EU HTA Harmonization Initiative: What is the Significance to Manufacturers of the New Directive?
Comparative clinical benefit assessments are at the core of Health Technology Assessments (HTAs) in Europe. HTAs are a multi-disciplinary process considering input and evidence from medical, social, and economic sources. They are used to inform the design of health policies that allow the safe and effective use of new technologies within individual health systems and […]
The Future of Work is Now. Are you Ready?
In today’s rapidly changing market, organizations and workforce experts alike are trying to determine how the future of work will transform. Based on conversations across the market and our in-depth research, KellyOCG has determined that there are four dimensions organizations need to consider when contemplating the “Future of Work”: technology, the workforce (including the multiple […]
Clinical Trials in Children with Impaired Mental Capacity
PRA has written a new white paper on conducting clinical trials with adolescents, specifically children with impaired mental capacity. In the majority of clinical trials we undertake, the consent process is fairly straightforward; however, we do conduct studies in patients who lack legal competence. This occurs most frequently in pediatric patients; in these cases the lack of […]
Prescribe Robust Distribution to Commercialize Your Orphan Drug
Finding a home for your biopharmaceutical company’s new orphan drug doesn’t just happen after it is FDA approved. The successful commercialization of your promising new drug requires a focused and well-planned distribution model. But first, some background. Orphan drugs treat rare diseases or medical conditions that affect fewer than 200,000 people a year in the […]
Adapting the Functional Services Model to Deliver Flexible Solutions
A mid-sized multinational client had historically resourced its monitoring services with multiple providers, including Covance, but wanted to move to one preferred partner for each of its global regions with a Functional Service Provider (FSP) model.
Challenges in Thought Leader Management – Data Analytics and Technology Can Help
Optimize the value of engagements with advanced analytics and proprietary, technology-enabled identification and profiling techniques.
Driving Drug Development Innovation Through Patient Centricity
The Innovation Imperative: The Future of Drug Development, is a recent data-driven report developed and released by The Economist Intelligence Unit and commissioned by PAREXEL. The report examines drug development today and evaluates innovations that can accelerate clinical trials, increase likelihood of launch and patient access and improve the productivity of drug development. The report […]
Breakthrough Drug Development Innovations: Increasing the Likelihood of Market Launch
By: Sy Pretorius, Chief Scientific & Medical Officer, PAREXEL Drug development today is facing serious challenges. The way new treatments are brought to market has become increasingly inefficient, lengthy and costly, with a high likelihood of failure. Meanwhile, pressures are mounting on companies to bring therapies to patients more quickly and cost effectively than ever […]
Avoid Enrollment Pitfalls by Engaging with Best-Fit Sites
Perhaps the single most important consideration in selecting a site is whether it can make its enrollment. Many don’t; in fact, 20-25 percent of all clinical studies close because they fail to meet enrollment targets.1 For decades, sponsors have found their “best fit” sites and returned to them for future studies. But in the era […]
Unlocking the potential of online communities – looking beyond the surface
While online communities have emerged as a critical component of understanding the experiences of people living with chronic conditions, there is so much more to learn and uncover beneath the surface. In this webinar, Health Union, a pioneer in creating open, online health communities (19 and counting), including migraine.com, multiplesclerosis.net and lungcancer.net, discusses the how […]
Medical Storytelling: Combining High Science and High Emotion for High Impact
During this presentation, the speakers will share their insights on transforming medical education content from a package insert rehash into a compelling, compliant medical story. They will highlight how you can take healthcare provider audiences from being passive listeners to active participants by Capturing and keeping their attention, reception, and recall Provocatively challenging healthcare providers […]
Utilizing a Protocol Cost Saving Analysis to Reduce Drug Development Costs
Over the years, studies have been conducted to ascertain the cost of research and development (“R&D”) required to bring a new drug to market. Experts disagree on the exact amount, but the consensus is that the figure is in the hundreds of millions to over a billion dollars. Pharmaceutical companies, biotech firms and anyone in […]
